Search

478 Result(s)
Sort by

Martin Stefanic

Martin Stefanic

Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
More Green Overview

More Green Overview

Our pillar MORE GREEN encompasses environmental initiatives that consider many different aspects.
What are lay summaries

What are lay summaries

Boehringer Ingelheim produces lay summaries of clinical trials, making complex information and data from clinical studies understandable for patients and carers.
Partnering for innovation in animal health

Partnering for innovation in animal health

Collaboration with external partners is a fundamental part of our innovation strategy in Animal Health. Learn more about the partners we are looking for.
Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Sales consultant about working with purpose

Sales consultant about working with purpose

Bok talks about how he found purpose in his career. After his father was diagnosed with cancer, he decided to work as an oncology sales consultant.
Nagoya Protocol

Nagoya Protocol

At Boehringer Ingelheim, environmental consciousness and protection are priorities in everything we do.
Our-position

Our-position

Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Pet parasites are still here. What's the risk?

Pet parasites are still here. What's the risk?

What's the risk of pet parasites? They’re a growing challenge due to climate change. Check how to protect your dog and cat from fleas, ticks and more.
InPedILD_trial_enrollment

InPedILD_trial_enrollment

First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents